TGA flags compounded Ozempic safety concerns

Pharmacists are being warned that they could be liable for any adverse outcome patients experience should they supply compounded semaglutide-like products  Reports that a telehealth provider plans to make compounded versions of Novo Nordisk’s Ozempic (semaglutide), have prompted the Therapeutic Goods Administration (TGA) to warn that such products “may contain undisclosed and potentially harmful ingredients”.